在肝细胞癌微环境中,IGF2BP1加速有氧糖解,以促进其免疫逃逸
Xuxing Ye1, Junmei Lin1, Yanping Chen2
1Department of Traditional Chinese Medicine, Jinhua Municipal Central Hospital, Jinhua, China.
Frontiers in immunology
|November 28, 2024
概括
这项研究表明,IGF2BP1通过增强有氧糖解和抑制免疫逃逸来促进肝细胞癌 (HCC) 的进展. 向IGF2BP1提供了一个潜在的策略来破坏瘤代谢和免疫逃避在HCC患者.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 异常的能量代谢,特别是有氧糖解,是癌症的标志,促进瘤发生.
- 在肝细胞癌 (HCC) 的有氧糖解和免疫逃逸中,N6 - - 甲基氨酸 (m6A) 修饰的作用在很大程度上仍未定义.
- IGF2BP1被确定为各种癌症的关键调节剂,但其在HCC代谢和免疫中的特定功能需要阐明.
研究的目的:
- 为了研究m6"读者"IGF2BP1在HCC有氧糖解中的调节作用.
- 确定IGF2BP1对HCC免疫逃生机制的影响.
- 阐明将IGF2BP1,新陈代谢和HCC中的免疫逃避联系在一起的分子途径.
主要方法:
- 通过测量葡萄糖吸收,乳酸盐生产,ATP生成和细胞外酸化率 (ECAR) 来评估有氧糖解.
- 评估CD8+ T细胞介导的细胞毒性,干扰素- (IFN-γ) 产量和B粒酶水平.
- 使用 luciferase 记者测定,免疫沉和染色体免疫沉 (ChIP) - PCR 确认分子相互作用.
主要成果:
- 增加IGF2BP1表达与HCC患者的预后不佳相关.
- IGF2BP1显著加速HCC的有氧糖解和抗氧化的抵抗力.
- IGF2BP1抑制CD8+T细胞介导的杀死,并通过调节c-Myc和随后的PD-L1表达,促进HCC细胞的生存.
结论:
- IGF2BP1在HCC中充当瘤原因子,推动新陈代谢重编程和免疫逃避.
- IGF2BP1稳定了c-Myc mRNA,导致c-Myc表达的增加,这反过来又调节了PD-L1.
- IGF2BP1代表了破坏HCC代谢和免疫交叉的有希望的治疗标.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.8K
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.2K
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Electron Transport Chain: Complex I and II
11.7K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
11.7K
Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
